Royal Bank of Canada
BNTC icon

Royal Bank of Canada’s Benitec Biopharma BNTC Stock Holding History

Royal Bank of Canada’s Portfolio BNTC Stock Details BNTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4K Sell
357
-1,765
-83% -$20.4K ﹤0.01% 6474
2025
Q4 		$29K Sell
2,122
-1,487
-41% -$20.6K ﹤0.01% 5837
2025
Q3 		$51K Buy
3,609
+3,541
+5,207% +$45.2K ﹤0.01% 5809
2025
Q2 		$1K Sell
68
-140
-67% -$1.96K ﹤0.01% 6854
2025
Q1 		$3K Buy
208
+35
+20% +$423 ﹤0.01% 6469
2024
Q4 		$2K Buy
+173
New +$1.87K ﹤0.01% 6694

Other funds holding BNTC

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
IAM
Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Royal Bank of Canada's BNTC Position: Q1 2026 in Review

Royal Bank of Canada reduced its Benitec Biopharma (BNTC) stake by 83% in Q1 2026, selling an estimated $20.4K and leaving 357 shares worth $4K. The position accounts for ﹤0.01% of the portfolio, ranked #6474.

Royal Bank of Canada first reported a position in BNTC in Q4 2024 and has held it in 6 quarters since. The position peaked at $51K in Q3 2025. 88 funds tracked by Wall St. Rank hold BNTC as of Q1 2026.

  • Royal Bank of Canada held 357 shares of Benitec Biopharma worth $4K as of Q1 2026.
  • Royal Bank of Canada sold 1,765 Benitec Biopharma shares in Q1 2026, an estimated $20.4K.
  • Benitec Biopharma made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #6474 holding.
  • Royal Bank of Canada first reported a position in Benitec Biopharma in Q4 2024 and has held it in 6 quarters since.
  • Royal Bank of Canada's Benitec Biopharma position peaked at $51K in Q3 2025.
  • 88 funds tracked by Wall St. Rank held Benitec Biopharma as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.